Reuters logo
BRIEF-Shanghai Fosun Pharmaceutical Group unit gets commercial and develop rights license
September 8, 2017 / 11:08 AM / 2 months ago

BRIEF-Shanghai Fosun Pharmaceutical Group unit gets commercial and develop rights license

Sept 8 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd :

* Says its controlling subsidiary got commercial, technical and develop rights license for Bremelanotide from Palatin Technologies, Inc

Source text in Chinese: goo.gl/JqF6cG

Further company coverage: (Beijing Headline News)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below